BioSpace News Archive

Nektar Therapeutics (NASDAQ: NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg) in two manuscripts in Nature Communications.

A machine-learning algorithm developed by an orthopedic surgeon at Hospital for Special Surgery (HSS) and his colleagues identified predictive factors associated with worse outcomes for patients with femoroacetabular impingement (FAI) of the hip who had arthroscopic surgery to treat it.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020, at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular atrophy patients from part 2 of the SUNFISH trial presented at the 2nd International Scientific Congress on Spinal Muscular Atrophy, (5 - 7 Feb) in Evry, France.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9th Annual Global Healthcare Conference in New York City.

CorCinch HFrEF Study Evaluating Safety of AccuCinch Ventricular Repair System in Heart Failure Patients

Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform

Recent severe challenges in 503B supply creating need for novel, more reliable, and safer alternatives

Former Genentech/Roche Chief Medical Officer and Head of Global Product Development will bring extensive global biopharma expertise to support Moderna’s late-stage development efforts

Option Care Health, Inc., the nation’s largest independent provider of home and alternate site infusion services, announced that it has completed the reverse 1-for-4 stock split of its shares of common stock, as previously disclosed in the Company’s filings with the Securities and Exchange Commission.

Seqirus announced that the U.S. Food and Drug Administration has approved AUDENZ™ Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A.1 AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic.